InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（1 笔）
内部人交易记录
董事已披露买入
1
已披露卖出
1
T+90 胜率
100%
T+90 平均收益
+49.3%
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
信号历史
Discover the detailed record of transactions filed by Mayer Arie, 董事. Director active across 1 company, notably Oramed Pharmaceuticals INC.. Aggregated, 9 filings have been logged. Split: 1 buy · 1 sell. Total volume traded: €77k. History available since 1 November 2021. The latest transaction was filed on 3 April 2023 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Mayer Arie
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报9 总计
30,000 股Common StockSEC:0001213900-26-001275:0
30,000 股Common StockSEC:0001213900-25-052624:0
30,000 股Common StockSEC:0001209191-24-001137:0
30,000 股Common StockSEC:0001209191-23-024935:0
5,009 股@ US$2.2213.3% 占其流量Common StockSEC:0001209191-23-022815:0
标准退出：2023年7月2日 (T+90)
12,000 股Common StockSEC:0001209191-22-043771:0
6,000 股Common StockSEC:0001213900-22-025289:0
3,000 股@ US$25.6086.7% 占其流量Common StockSEC:0001213900-22-025288:0
6,000 股Common StockSEC:0001213900-22-000820:0
9 条申报中的 9 条
About Mayer Arie
Mayer Arie is Administrateur at Oramed Pharmaceuticals INC. (XNAS) and is also listed there as Director. The record shows 9 filings in total, and across the 9 sampled filings between 2022-01-05 and 2026-01-05, the aggregated amounts are EUR 10190 in buys and EUR 66455 in sells, with the modal transaction nature listed as Attribution.
